HIV clinic-based extended-release naltrexone versus treatment as usual for people with HIV and opioid use disorder: a non-blinded, randomized non-inferiority trial.

ABSTRACT:

Background and aim

Opioid agonist medications for treatment of opioid use disorder (OUD) can improve human immunodeficiency virus (HIV) outcomes and reduce opioid use. We tested whether outpatient antagonist treatment with naltrexone could achieve similar results.

Design

Open-label, non-inferiority randomized trial.

Setting

Six US HIV primary care clinics.

Participants

A total of 114 participants with untreated HIV and OUD (62% male; 56% black, 12% Hispanic; positive for fentanyl (62%), other opioids (47%) and cocaine (60%) at baseline). Enrollment halted early due to slow recruitment.

Intervention

HIV clinic-based extended-release naltrexone (XR-NTX; n = 55) versus treatment as usual (TAU) with buprenorphine or methadone (TAU; n = 59).

Measurements</

SUBMITTER: Korthuis PT 

PROVIDER: S-EPMC9314106 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature